Scancell Share Discussion Threads

[marcusl2] 28/11/2024 16:29

Exactly Chill. It would be nice if we can keep this thread to only Scancell relevant posts. We can always live in hope!

[chilltime] 28/11/2024 16:21

EG

They will be seeing ongoing data in Scib1, Iscib, Modi combo and monos, all of which is price sensitive.

Then you have, anon glymab deal pending yes or no. Genmab phase 1 timelines plus payment, deals on other Glymabs. scib talks and so on.

Scancell have gone from chatting to Genmab over a Glymab to intense interest across most of their assets.

The obvious route for the CEO is options

[chilltime] 28/11/2024 16:15

Nigel

News due within closed out time limits, plus they are in multiple discussions with various large companies and pending plus ongoing results data

So directors will be closed out for most of the time over the next year.

[rogerbridge] 28/11/2024 16:15

I imagine Phill will be going through everything we have in trials, in development, or proposed development to ensure the best return for shareholders.

Of course, he may be negotiating with a major, news due next month?

[nigelpm] 28/11/2024 15:46

Surprised to see a lack of Director buying. If it really is as good as some think you'd have thought they'd be backing up the truck.

[chilltime] 28/11/2024 15:33

Plas

That paper on Modi 2.

I’ve had a read but not picked through it.

Cancers have a myriad of different biological aspects, A,,B,C………….. and on.

Research tries to identify targets applicable to cancerous cells and not healthy cells, then develop a therapy that will lock onto the target, EG Type A1, B2, C11 etc.

In the case of Modi 2 it seems they have identified 3 targets which appear in the cancers mentioned. T cell responses going on the attack to the target, thus killing cancerous cells.

I’d have to check carefully but it gave 3 mouse model successes, I guess 3 different targets to produce overall survival of 40%, 70% and 100%.

The parallel part of that paper was about the difficulties of mass vaccine production, due to the agglomeration issues and size of particles, which has been resolved through Snapvax technology, which makes the vaccine viable with commercial production capability.

That was one quick read, I’d have to pick through personally to join the dots.

On a wider point, if Scib and Modi work in these combis then it points to the Scib2, Modi2 vaccines working too.

In other words viable, efficacious, safe, low cost production vaccine platforms for multiple cancers.

[supernumerary] 28/11/2024 14:57

Probably just feeling a bit down :¬(

[markingtime] 28/11/2024 14:29

Could I just point out to those who struggle with this that this form of cancer affects the prostate.Anyone who thinks it is prostrate is simply lying.

[inanaco] 28/11/2024 14:07

Industry operates on Costs . dictated by

cost of labour
Labour Regulations
Labour Skills via quality of education
Innovated people
Income tax levels
Ni
Union Power
Council Tax
Cost of Insurance
General Red tape
Corp Tax
Ni Tax
CGT tax
Cost of Energy
Cost of Finance
Currency stability

all of which is controlled by the Government

it alone has the power to influence

[willoicc] 28/11/2024 13:51

We should also support our own industries instead of buying so much from abroad.

We need to create more wealth, starting with cars.

Our trade deficit with the EU is £ 100 billion. Imagine how much we could add to our GDP figures if we made a lot more ourselves.

When we send our money abroad, it never comes back.

That is why we are getting hammered for more tax and it will only get worse.

[rogerbridge] 28/11/2024 13:37

By the way Inanaco, the UK haave dropped down to 29th possition on the world
per capita leauge tables.

Maybe we should live within our means and stop touring the world stating that we are leading the world in certain area's.

[marcusl2] 28/11/2024 09:38

Modi-1

RCC (Kidney), TNBC (Breast), Head and Neck, Ovarian cancers.

iScib-1 Melanoma

Scib-2 NYESO positive solid tumours, so neuroblastoma, myeloma, metastatic melanoma, synovial sarcoma, bladder cancer, esophageal cancer, hepatocellular cancer, head and neck cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, and breast cancer


SC129 Pancreatic

SC134 SCLC Lung

SC2811 numerous

SC27 55% colorectal, 86% gastric, 38% ovarian and 46% of breast cancer

Avidimab

Glymabs additional

[marcusl2] 28/11/2024 09:29

Modi-2

We demonstrate that human lung, colorectal, breast and prostate tumours express the Modi-2 target antigens and propose the Modi-2 vaccine has potential for translation into clinic in several cancer indications.

[sci102] 28/11/2024 09:29

Exactly the same thing applies bermuda. And by the way your examples are from people selling services, it isn't that you can't be granted the patent, it's what claims are actually granted and to what extent they offer protection. And even then, not being able to market as such does not mean it cannot be used in exactly the same way.

[marcusl2] 28/11/2024 09:28

27 November 2024
Modi-2 a vaccine stimulating CD4 responses to homocitrullinated self epitopes as therapy for solid cancers

Modi-2 SNAPvax formulations induced potent anti-tumour responses with 40%, 100% and 70% overall survival rates in three aggressive tumour models, B16 HHDII iDP4, CT26 and 4T1, respectively. Our data have also demonstrated that Modi-2 SNAPvax formulations dramatically enhanced infiltration of TILs in particular of total CD4 T cells, and both CD45+ immune cells and CD45- non-immune cells showed a significant increase in MHC class II expression within tumours suggesting the CD4 responses stimulated by vaccination mediate an alteration of the tumour microenvironment.

The nature of homocitrullination in the tumour environment suggests a role for Modi-2 in patients with existing tumours but the majority of patients with existing solid and untreatable tumours will likely have established tumour intrinsic mechanisms of immune evasion. These patients would therefore likely require combination with other interventions such as checkpoint blockade therapies to help overcome the immune suppression associated existing tumour mass in combination with vaccination to generate de novo tumour specific immune responses.

[bermudashorts] 28/11/2024 09:07

Re. Your 564 - we're not discussing repurposed drugs, this isn't a case of repurposing SCIB1 for new indications. That's a different category altogether when it comes to evergreening. Scancell have filed a new combination patent.

[torquayfan] 28/11/2024 08:56

Roger I thought so too.

[bermudashorts] 28/11/2024 08:53

Look all I know is that Lindy Durrant confirmed in a presentation to shareholders and analysts that they have filed a new patent for SCIB1 in combination which gives them the option to proceed with either SCIB1 or iSCIB1+. They clearly have done this based on advice and guidance from their patent attorneys and in the expectation that it will be granted following due process.

What are we meant to believe? Scancell's version or yours which is that 'additional patents of scib1(which by the way they have not even been granted yet), they are there to built upon previous IP which is expiring and they can't stand on their own'

[sci102] 28/11/2024 08:37

"For repurposed drugs ‘Use’ patents may be filed to protect the ‘method of use’ of the drug for the new indication, however, use patents are typically weaker than composition-of-matter patents and are therefore more costly for the companies to enforce [99]. Use patents also do not prevent off-label prescriptions, in which medications are prescribed for indications or populations for which they have no regulatory approval for [102]. In the case of drug repurposing, this can mean prescription of the generic version of a drug instead of the more expensive patented alternative which has gone through the regulatory approval process for the new indication and achieved market exclusivity. To tackle this problem pharmaceutical companies are legally prohibited from advertising off-label indications, although physicians are able to prescribe its off-label uses, supported by evidence of their efficacy in it new indications [103] which may take away from potential profits."



As I said, the key is to make. The hospitals will then use it. The only status that prevents marketing AND use is Orphan drug for 6 years (the FDA does have a few other, but all of them provide protection from a few months and up to 3 years).

[rogerbridge] 28/11/2024 08:25

That’s really good news.

[bermudashorts] 28/11/2024 07:58

'It’s quite common for multiple drugs to be prescribed together because they control different aspects of a condition, or they have a magnified effect when taken together—known as synergism—that is more than the sum of its parts. In either case, this provides an attractive opportunity for drug companies to create combinations of patented drugs and bring them to market as a newly patented product. A recent example of this is Symbyax—a combination of the drugs olanzapine (Zyprexa) and fluoxetine (Prozac)—that is indicated for the treatment of bipolar disorder.'

[ivyspivey] 28/11/2024 07:57

SCI what I mean apart from the Science is advanced is that SCLP has a much better balanced and experienced team to make progress re commercialisation of assets rather than simply trying to endlessly improve on the Science which I think they have been guilty of in the past

[sci102] 28/11/2024 07:48

I am not mistaken Bermuda. I KNOW this space. Time (and the specific claims that are actually granted) will tell.